Liraglutide modulates olfactory ensheathing cell migration with activation of ERK and alteration of the extracellular matrix

Tseng, Yu‐Ting; Chen, Mo; Lai, Richard; Oieni, Francesca; Smyth, Graham; Anoopkumar‐Dukie, Shailendra; John, James St; Ekberg, Jenny

doi:10.1016/j.biopha.2021.111819

Cited by 7 publications

(4 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…OECs are the glial cells of the primary olfactory system, and its transplantation is a promising strategy for functional repair following spinal cord and peripheral nerve injuries ( Chou et al, 2014 ). Tseng et al (2021) observed stimulatory effects of liraglutide (100 nM) on the migration of primary cultured and lined OECs with activation of the extracellular signal-regulated kinases (ERK) pathway and modulation of extracellular matrix proteins (upregulation of laminin-1 and downregulation of type IV collagen). These findings imply the potential efficacy of liraglutide and other GLP-1RAs for improving OECs transplantation outcomes, including remyelination.…”

Section: Glp-1ras As Favorable Factors For Myelin Formation and Maint...mentioning

confidence: 99%

“…To our knowledge, this is the first study to introduce GLP-1RAs as oligodendrocyte-protective molecules. Because the expression of GLP-1R in myelin-forming oligodendrocytes has been implicated ( Smith et al, 2022 ) and the stimulatory effects of GLP-1RAs on Schwann cells and OECs have been delineated ( Pan et al, 2020 ; Takaku et al, 2021 ; Tseng et al, 2021 ), it seems plausible that the agents can directly act on oligodendrocytes and their progenitor cells to promote remyelination under MS conditions.…”

Section: Potential Efficacy Of Glp-1ras Toward Demyelinating Disordersmentioning

confidence: 99%

See 1 more Smart Citation

Glucagon-Like Peptide-1 Receptor Agonists as Potential Myelination-Inducible and Anti-Demyelinating Remedies

Sango

Takaku

Tsukamoto

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) were developed as insulinotropic and anti-hyperglycemic agents for the treatment of type 2 diabetes, but their neurotrophic and neuroprotective activities have been receiving increasing attention. Myelin plays a key role in the functional maintenance of the central and peripheral nervous systems, and recent in vivo and in vitro studies have shed light on the beneficial effects of GLP-1RAs on the formation and protection of myelin. In this article, we describe the potential efficacy of GLP-1RAs for the induction of axonal regeneration and remyelination following nerve lesions and the prevention and alleviation of demyelinating disorders, particularly multiple sclerosis.

show abstract

Section: Glp-1ras As Favorable Factors For Myelin Formation and Maint...mentioning

confidence: 99%

Section: Potential Efficacy Of Glp-1ras Toward Demyelinating Disordersmentioning

confidence: 99%

Glucagon-Like Peptide-1 Receptor Agonists as Potential Myelination-Inducible and Anti-Demyelinating Remedies

Sango

Takaku

Tsukamoto

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…A study of OEC transplantation combined with cyclosporine A in rats with SCI showed that cyclosporine A played an immunosuppressive role, which improved the survival rate of the OECs, enhanced the protective effect of the OECs on neurons and axons, and increased the number of 5‐hydroxytryptamine axons at the edge of the glial scar (Khankan et al., 2016). It has also been reported that liraglutide can stimulate OEC migration, re‐model the extracellular matrix to promote cell migration, and possibly become more conducive to axonal regeneration (Tseng et al., 2021).…”

Section: Oec‐based Comprehensive Therapymentioning

confidence: 99%

Spinal cord injury: Olfactory ensheathing cell‐based therapeutic strategies

Chen,

Liu,

Stavrinou

et al. 2023

J of Neuroscience Research

View full text Add to dashboard Cite

Spinal cord injury (SCI) is a highly disabling neurological disorder that is difficult to treat due to its complex pathophysiology and nerve regeneration difficulties. Hence, effective SCI treatments are necessary. Olfactory ensheathing cells (OECs), glial cells derived from the olfactory bulb or mucosa, are ideal candidates for SCI treatment because of their neuroprotective and regenerative properties, ample supply, and convenience. In vitro, animal model, and human trial studies have reported discoveries on OEC transplantation; however, shortcomings have also been demonstrated. Recent studies have optimized various OEC transplantation strategies, including drug integration, biomaterials, and gene editing. This review aims to introduce OECs mechanisms in repairing SCI, summarize the research progress of OEC transplantation‐optimized strategies, and provide novel research ideas for SCI treatment.

show abstract

“…Similarly, lysophosphatidic acid (LPA) is produced at the injury site, and has been reported to promote migration and proliferation of OECs via extracellular signal-regulated kinase (ERK1/2) signaling 106 while also facilitating the homing of OECs to the injury site 107 . We recently showed that liraglutide, a glucagon-like peptide-1 receptor agonist, could stimulate OEC migration by reducing time in arrest, upregulating laminin-1, and activating the ERK pathway 108 . Another approach to augment OEC migration at the site of injury is to genetically modify cells.…”

Section: Introductionmentioning

confidence: 99%

Designing Olfactory Ensheathing Cell Transplantation Therapies: Influence of Cell Microenvironment

et al. 2022

View full text Add to dashboard Cite

Olfactory ensheathing cell (OEC) transplantation is emerging as a promising treatment option for injuries of the nervous system. OECs can be obtained relatively easily from nasal biopsies, and exhibit several properties such as secretion of trophic factors, and phagocytosis of debris that facilitate neural regeneration and repair. But a major limitation of OEC-based cell therapies is the poor survival of transplanted cells which subsequently limit their therapeutic efficacy. There is an unmet need for approaches that enable the in vitro production of OECs in a state that will optimize their survival and integration after transplantation into the hostile injury site. Here, we present an overview of the strategies to modulate OECs focusing on oxygen levels, stimulating migratory, phagocytic, and secretory properties, and on bioengineering a suitable environment in vitro.

show abstract

Liraglutide modulates olfactory ensheathing cell migration with activation of ERK and alteration of the extracellular matrix

Cited by 7 publications

References 93 publications

Glucagon-Like Peptide-1 Receptor Agonists as Potential Myelination-Inducible and Anti-Demyelinating Remedies

Glucagon-Like Peptide-1 Receptor Agonists as Potential Myelination-Inducible and Anti-Demyelinating Remedies

Spinal cord injury: Olfactory ensheathing cell‐based therapeutic strategies

Designing Olfactory Ensheathing Cell Transplantation Therapies: Influence of Cell Microenvironment

Contact Info

Product

Resources

About